[A19-55] Dolutegravir/lamivudine (HIV infection) - Benefit assessment according to §35a Social Code Book V
Last updated 06.02.2020
Project no.:
A19-55
Commission:
Commission awarded on 04.07.2019 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Adults and adolescents with HIV-1 infection whose virus has no known or suspected resistance to integrase inhibitors or lamivudine
Treatment-naive adults: proof of minor added benefit. Treatment-naive adolescents and pretreated adults and adolescents: added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A19-103 | Dolutegravir/lamivudine (HIV infection) - Second Addendum to Commission A19-55 | Commission completed |
| A19-102 | Dolutegravir/lamivudine (HIV infection) - Addendum to Commission A19-55 | Commission completed |
Federal Joint Committee (G-BA)
2020-02-06 A G-BA decision was published.